ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function.
The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome, and liver diseases (such as Non-Alcoholic SteatoHepatitis, NASH).
Liver-related infectious diseases such as chronic Hepatitis B and Hepatitis D are also addressed with Vonafexor.
Company Details
- Employees
- 38
- Founded
- -
- Address
- 60 Avenue Rockefeller, 69008 Lyon, France, Bioserra 1,bâtiment B,france
- Phone
- 33437700219
- co****@****rma.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- enyopharma.com
- HQ
- Lyon, Rhône-Alpes
Enyo Pharma Questions
Enyo Pharma's helpline number is 33437700219
Enyo Pharma's website is enyopharma.com
Enyo Pharma's LinkedIn profile is https://fr.linkedin.com/company/enyo-pharma
Enyo Pharma has
38 employees.
View email and phone details for 38
employees at Enyo Pharma.
Enyo Pharma's industry is
Biotechnology Research
Enyo Pharma's top competitors are
Phaxiam Therapeutics,
Abivax,
Ose Immunotherapeutics,
Adocia,
Maat Pharma,
Fabentech,
Bioaster,
Cellectis,
Enterome,
Innate Pharma.
Enyo Pharma's support email address is contact@enyopharma.com
Enyo Pharma's categories are Biotechnology Research
Enyo Pharma's founding year is 2014
